1. Home
  2. SUPN vs CENTA Comparison

SUPN vs CENTA Comparison

Compare SUPN & CENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • CENTA
  • Stock Information
  • Founded
  • SUPN 2005
  • CENTA 1955
  • Country
  • SUPN United States
  • CENTA United States
  • Employees
  • SUPN N/A
  • CENTA N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • CENTA Consumer Specialties
  • Sector
  • SUPN Health Care
  • CENTA Consumer Discretionary
  • Exchange
  • SUPN Nasdaq
  • CENTA Nasdaq
  • Market Cap
  • SUPN 2.1B
  • CENTA 2.0B
  • IPO Year
  • SUPN 2012
  • CENTA 1993
  • Fundamental
  • Price
  • SUPN $37.74
  • CENTA $30.69
  • Analyst Decision
  • SUPN Hold
  • CENTA Strong Buy
  • Analyst Count
  • SUPN 1
  • CENTA 5
  • Target Price
  • SUPN $36.00
  • CENTA $41.50
  • AVG Volume (30 Days)
  • SUPN 376.5K
  • CENTA 317.6K
  • Earning Date
  • SUPN 02-25-2025
  • CENTA 02-05-2025
  • Dividend Yield
  • SUPN N/A
  • CENTA N/A
  • EPS Growth
  • SUPN 130.79
  • CENTA N/A
  • EPS
  • SUPN 1.07
  • CENTA 1.62
  • Revenue
  • SUPN $651,972,000.00
  • CENTA $3,200,460,000.00
  • Revenue This Year
  • SUPN $7.82
  • CENTA $2.67
  • Revenue Next Year
  • SUPN N/A
  • CENTA $2.19
  • P/E Ratio
  • SUPN $35.28
  • CENTA $19.24
  • Revenue Growth
  • SUPN 6.79
  • CENTA N/A
  • 52 Week Low
  • SUPN $25.53
  • CENTA $27.70
  • 52 Week High
  • SUPN $39.37
  • CENTA $41.03
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 57.78
  • CENTA 38.69
  • Support Level
  • SUPN $36.48
  • CENTA $30.27
  • Resistance Level
  • SUPN $38.68
  • CENTA $31.27
  • Average True Range (ATR)
  • SUPN 1.06
  • CENTA 1.00
  • MACD
  • SUPN 0.09
  • CENTA -0.20
  • Stochastic Oscillator
  • SUPN 68.46
  • CENTA 29.83

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About CENTA Central Garden & Pet Company Nonvoting

Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.

Share on Social Networks: